Skip to main content
. 2012 Sep 25;7(9):e46185. doi: 10.1371/journal.pone.0046185

Figure 5. The effect of dasatinib on survival and disease progression in G93A mice.

Figure 5

Rotarod activity, grip strength, body weight, and survival rate in G93A mice with or without dasatinib treatment (0, 5, 15, and 25 mg/(kg·day)). Survival of G93A mice was improved by dasatinib at a dose of 25 mg/(kg·day) compared with vehicle treatment (Log-rank test, P<0.01, 25 mg/(kg·day) vs. vehicle), whereas a lower dose of dasatinib (5 mg/(kg·day)) had no significant effect on life span. Weight loss was also ameliorated by dasatinib at a dose of 25 mg/(kg·day) compared with vehicle treatment (2-way ANOVA, P<0.01, 25 mg/(kg·day) vs. vehicle). The administration of dasatinib at 25 mg/(kg·day) similarly ameliorated grip strength (2-way ANOVA, P<0.01, 25 mg/(kg·day) vs. vehicle). The difference in physical function between the groups as assessed by rotarod was not significant by 2-way ANOVA, although a beneficial tendency of dasatinib was observed.